Dr. Ryan Zeidan Ph.D. serves as Chief Development Officer of the Company. Dr. Zeidan was promoted to Chief Development Officer. From October 2016 through June 2018, he served as Executive Director, Global Program Lead at Celgene Corporation, where he oversaw the development of two late-stage oncology assets in a variety of tumor types, including advancing both assets to Phase 3 registration studies. Prior to Celgene Corporation, from January 2012 to October 2016, Dr. Zeidan was Executive Director, Global Strategy and Operations, at Novartis Oncology, where he supported the company in business-critical activities, including developing the five-year strategic plan and investor relations matters. From January 2009 to January 2012, Dr. Zeidan served as a Project Leader at the Boston Consulting Group, where he focused on pharmaceutical and biotech strategy. Dr. Zeidan holds a Ph.D. in chemistry and chemical engineering from the California Institute of Technology, and dual bachelor’s degrees in chemistry and chemical engineering from the Massachusetts Institute of Technology.
As the Chief Development Officer of Millendo Therapeutics, the total compensation of Ryan Zeidan at Millendo Therapeutics is $849,145. There are 2 executives at Millendo Therapeutics getting paid more, with Julia Owens having the highest compensation of $2,381,880.
Ryan Zeidan is 40, he's been the Chief Development Officer of Millendo Therapeutics since 2019. There are 14 older and no younger executives at Millendo Therapeutics. The oldest executive at Millendo Therapeutics, Inc. is John Howe, 77, who is the Independent Director.
Ryan's mailing address filed with the SEC is C/O MILLENDO THERAPEUTICS, INC, 110 MILLER AVENUE, SUITE 100, ANN ARBOR, MI, 48104.
Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.
Millendo Therapeutics executives and other stock owners filed with the SEC include: